Oryzon Genomics & Columbia Psychiatry Launch Schizophrenia-Focused Precision Medicine Research

Biopharmaceutical company Oryzon Genomics, S.A., is collaborating with researchers from Columbia University in New York on a precision medicine therapy project focused on schizophrenia. The research will focus on a gene, SETD1A, linked to susceptibility for schizophrenia. The goal is to characterize the neuropsychiatric symptoms of people who have the SETD1A gene mutations.

The project seeks to build a foundation for a subsequent precision psychiatry clinical trial with vafidemstat, an LSD1 inhibitor developed by Oryzon for SETD1A-associated psychiatric disorders. The first stage will further characterize—at the molecular level—the therapeutic actionability of the SETD1A regulator protein encoded . . .